concentration for at least 2 weeks.

4. Use of fulvestrant in the preparation of a pharmaceutical formulation
for the treatment of a benign or malignant disease of the breast or reproductive tract by intra-muscular administration, wherein the pharmaceutical formulation comprises fulvestrant, 30% or less weight of a
pharmaceutically-acceptable alcohol per volume of formulation, at
least 1% weight of a pharmaceutically-acceptable non-aqueous ester
solvent miscible in a ricinoleate vehicle per volume of formulation and
a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45 mgml-1 of fulvestrant.